(Q33845845)

English

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

International Collaborative Ovarian Neoplasm Group

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

1 August 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

360

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

9332

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

505-515

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18-29 (1999)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimates of the worldwide incidence of 25 major cancers in 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of doxorubicin on survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A new standard of care for treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909738-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(02)09738-6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33845845&oldid=1979924342"